Reprogramming TAMs towards an antitumorigenic M1-like phenotype and overcoming CD8+ T cell exhaustion are crucial challenges in developing effective immunotherapies for HBV-related hepatocellular carcinoma (HCC). The gene discussed is CD8A; the disease is hepatocellular carcinoma.